Product logins

Find logins to all Clarivate products below.


Dyslipidemia | Treatment Algorithms: Claims Data Analysis | Hypertriglyceridemia | US | 2019

Hypertriglyceridemia is characterized by elevated triglyceride (TG) levels. In addition to lifestyle changes, current treatment focuses on improving patients’ TG levels with the aim to reduce the associated CV risk. Fibrates, statins, and omega-3 fatty acids are predominantly prescribed to manage hypertriglyceridemia patients. Using a longitudinal claims data analysis, we demonstrate how hypertriglyceridemia is being treated in the United States and provide insight into what is driving current prescribing practices for newly diagnosed and recently treated patients.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed hypertriglyceridemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed hypertriglyceridemia patients?
  • How has Vascepa been integrated into the hypertriglyceridemia treatment algorithm compared with the available generic omega-3 fatty acids?
  • What percentage of hypertriglyceridemia patients receive drug therapy within six months of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of hypertriglyceridemia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated hypertriglyceridemia patients?

Geographies: United States

Real World Data: Longitudinal patient-level claims data analysis

Key Drugs Covered: Fibrates, omega-3-acid ethyl esters (Lovaza), Vascepa, statins, niacin derivatives

Key Analysis Provided

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.

Related Market Assessment Reports

Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or functional loss of melanocytes. Given its visible manifestations, the disease is associated with a substantial…